With the current average volume of 894.162K, the ARCA biopharma, Inc. (ABIO) stock is being traded at $3.o2 in the pre-market with an increase of 0.08$ (2.72%) as compared to the close of 2.94$ in the market last day. The company has released its Q2 financial details. According to the report they have had an increase of $13.2M from $49.1M in December 2020 to a total amount of $63.2M. The company believes that the cash and cash equivalents would be enough to fund their operation in 2022. They have released updates on their clinical lab tests regarding Covid-19 and Cardiovascular Diseases
Throughout history, a lot of different diseases have come forward that have been lethal for humans. Many of these diseases have been tackled. But a lot of them still need to be researched more to find their solutions and to create medicines for them. Huge advancements were brought in the industry with the discovery of DNA and then later on how to alter and isolate the structure to modify the genetic code. This was to bring in genetic changes in the hope to remove any diseases that may be transferable to the next generation. Different companies and organizations have started working on its solutions with the hope to eradicate these diseases from their roots. ARCA biopharma, Inc. (ABIO) is one of such a company that is currently trying to make its way through clinical trials and its research.
About ABIO Stock
In 2004 Arca Biopharma was founded on the belief of a precision medicine approach. A technique for the development of medicine according to the individual characteristic traits of a person that helps in developing a much more effective treatment. It is a clinical biopharmaceutical company that has been working in the R&D sector to provide new research and methodologies. They are also conducting trials for the evaluation of new medicines. The company ARCA biopharma, Inc. (ABIO)has its headquarters located in Westminster Colorado.
New Research and Pipeline Projects
The company is currently working on cNAPc2 and Heparin for patients with COVID-19. They started conducting clinical trials in December 2020 with the grant of FAST TRACK DESIGNATION by FDA in NOV 2020. They are also working on the trials of Atrial Fibrillation for cardiovascular diseases with the help of “GENCARO; a beta blocker. The company has also released a number of publications. Being partners with the University of Colorado they are working together on different fields hoping to achieve viable results.
